PGK1 and non-small cell lung carcinoma: Furthermore, MetaLnc9 directly binds phosphoglycerate kinase 1 (PGK1) and inhibits its ubiquitin-mediated degradation, leading to the activation of the AKT/mTOR signaling pathway in NSCLC cells (Fig. 3B) [32].